Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics. (16th March 2021)

• Record Type: Journal Article
• Authors: Nolin, Marc-André; Demers, Marie-France; Rauzier, Chloé; Bouchard, Roch-Hugo; Cadrin, Camille; Després, Jean-Pierre; Roy, Marc-André; Alméras, Natalie; Picard, Frédéric
• Is Part Of: World journal of biological psychiatry. Volume 22:Number 3(2021)
• Page Start: 175
• Page End: 182
• Publication Date: 2021-03-16
• Subjects: Humans -- dyslipidaemia -- obesity -- antipsychotics -- cardiometabolic risk; Biological psychiatry -- Periodicals; Biological Psychiatry -- Periodicals; 616.89
• DOI: 10.1080/15622975.2020.1770858
• Languages: English
• ISSNs: 1562-2975

Abstract

Abstract: Objectives: Second generation antipsychotics (SGAs) induce weight gain and dyslipidemia, albeit with important intervariability. Insulin-like growth factor binding protein (IGFBP)-2 is proposed as a circulating biomarker negatively associated with waist circumference and hypertriglyceridemia. Thus, we tested whether metabolic alterations developed upon the use of SGAs are associated with plasma IGFBP-2 levels. Methods: A cross-sectional study was performed in 87 men newly diagnosed with schizophrenia and administered for approximately 20 months with olanzapine or risperidone as their first antipsychotic treatment. Plasma IGFBP-2 concentration, anthropometric data, as well as glucose and lipid profiles were determined at the end of the treatments. Results: IGFBP-2 levels were similar between patients using olanzapine or risperidone and were negatively correlated with waist circumference, insulin sensitivity, and plasma triglycerides (TG). A higher proportion of men with a hypertriglyceridemic (hyperTG) waist phenotype was found in patients with IGFBP-2 levels lower than 220 ng/mL (43% for olanzapine and 13% for risperidone) compared to those with IGFBP-2 above this threshold (10% and 0%, respectively). Conclusions: IGFBP-2 may have a role in altering metabolic risk in schizophrenic patients using SGAs. Longitudinal studies are required to evaluate whether IGFBP-2 can predict the development of a hyperTG waist phenotype in this population.